The 4,000-Year-Old Wonder Drug: How Aspirin is Becoming a Modern Shield Against Cancer

Vithanage Erandi Kawshalya Madhushani, Jadetimes Staff

---

Alamy

The Evolution of a Remedy Aspirin’s journey began 4,400 years ago as willow bark extract used by ancient Mesopotamians to treat pain. Over the centuries, it evolved from a powdered bark into a mass-produced synthetic drug. While it became a staple for treating fevers and cardiovascular risks, modern science has uncovered a revolutionary third act: its potent ability to prevent the onset and spread of cancer.

Protecting the Genetically Vulnerable A major breakthrough involves Lynch Syndrome, a genetic condition that significantly increases the risk of bowel cancer. A landmark 10-year clinical trial led by Professor John Burn at Newcastle University revealed that a daily dose of aspirin could halve the risk of colorectal cancer in these patients. This evidence has already influenced global health policies, with the UK now recommending early aspirin intervention for high-risk individuals.

Preventing Recurrence and Metastasis Recent studies have shifted focus to patients who have already been diagnosed with cancer. Professor Anna Martling’s research in Sweden demonstrated that aspirin can reduce the risk of cancer recurrence by more than 50% in patients with specific genetic mutations. Consequently, as of January 2026, Sweden has implemented mandatory genetic screening for bowel cancer patients to determine if low-dose aspirin should be part of their recovery protocol.

The Science Behind the "Mystery" Researchers have identified two primary biological mechanisms that explain aspirin’s anti-cancer effects:

1. Inhibiting Cell Growth: Aspirin blocks the Cox-2 enzyme, which prevents the production of compounds that signal cells to grow uncontrollably.

   
   

2. Unmasking Cancer Cells: Aspirin inhibits thromboxane, a clotting factor. Normally, cancer cells "hide" inside blood clots to escape detection. By thinning the blood, aspirin renders these cells visible to the immune system’s T-cells, which can then hunt and destroy them.

Future Outlook and Safety Caution Ongoing global trials, involving over 11,000 participants in the UK, Ireland, and India, are currently testing aspirin’s effectiveness against breast, prostate, and gastroesophageal cancers. Despite these promising results, experts stress that aspirin is not a "one-size-fits-all" cure. Due to risks of internal bleeding and stomach ulcers, a daily regimen should only be started under strict medical supervision.